Press Releases Valneva

Equities

VLA

FR0004056851

Market Closed - Euronext Paris Other stock markets 11:37:18 2024-04-29 EDT			After market 16:00:00
3.466 ^EUR	+0.64%		3.468	+0.06%

04-11	Valneva: Deep Track Biotechnology Master holds less than 5% of the capital	CF
03-26	Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valneva : Document AMF CP. 2024E960493	04-16	PU
World Vaccine Congress Washington: Antibody persistence of a single-dose live-attenuated chikungunya virus vaccine in adults	04-04	PU
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	03-26	AQ
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	03-26	GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F	03-25	GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F	03-25	AQ
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	03-21	AQ
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.	03-21	GL
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	03-20	GL
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	03-20	AQ
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed	03-18	GL
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences	03-04	GL
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences	03-04	AQ
U.S. CDC Advisory Committee Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ	03-01	AQ
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®	02-29	GL
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance	02-15	GL
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance	02-15	AQ
Valneva Announces Sale of Priority Review Voucher for $103 Million	02-05	GL
Valneva Announces Sale of Priority Review Voucher for $103 Million	02-05	AQ
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine	01-10	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Valneva

Equities

VLA

FR0004056851

Press Releases

Filters